Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice
Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, imm...
Uloženo v:
| Vydáno v: | Frontiers in oncology Ročník 9; s. 1512 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Frontiers Media S.A
24.01.2020
|
| Témata: | |
| ISSN: | 2234-943X, 2234-943X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, immune evasion, and tumor metastasis has prompted various studies to investigate their clinical significance as a biomarker of predictive and prognostic value across different cancer types. Yet, the methodologies to investigate the polarization phenomena in solid tumor tissue vary. Nonetheless, quantifying the ratio of M1 to M2 TAMs has emerged to be a prevailing parameter to evaluate this polarization phenomena for clinical application. This mini-review focuses on recent studies exploring clinical significance of M1/M2 TAM ratio in human cancer tissue and critically evaluates the technicalities and challenges in quantifying this parameter for routine clinical practice. Immunohistochemistry appears to be the preferred methodology for M1/M2 TAM evaluation as it is readily available in clinical laboratories, albeit with certain limitations. Recommendations are made to standardize the quantification of TAMs for better transition into clinical practice and for better comparison among studies in various populations of patients and cancer types. |
|---|---|
| AbstractList | Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, immune evasion, and tumor metastasis has prompted various studies to investigate their clinical significance as a biomarker of predictive and prognostic value across different cancer types. Yet, the methodologies to investigate the polarization phenomena in solid tumor tissue vary. Nonetheless, quantifying the ratio of M1 to M2 TAMs has emerged to be a prevailing parameter to evaluate this polarization phenomena for clinical application. This mini-review focuses on recent studies exploring clinical significance of M1/M2 TAM ratio in human cancer tissue and critically evaluates the technicalities and challenges in quantifying this parameter for routine clinical practice. Immunohistochemistry appears to be the preferred methodology for M1/M2 TAM evaluation as it is readily available in clinical laboratories, albeit with certain limitations. Recommendations are made to standardize the quantification of TAMs for better transition into clinical practice and for better comparison among studies in various populations of patients and cancer types.Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, immune evasion, and tumor metastasis has prompted various studies to investigate their clinical significance as a biomarker of predictive and prognostic value across different cancer types. Yet, the methodologies to investigate the polarization phenomena in solid tumor tissue vary. Nonetheless, quantifying the ratio of M1 to M2 TAMs has emerged to be a prevailing parameter to evaluate this polarization phenomena for clinical application. This mini-review focuses on recent studies exploring clinical significance of M1/M2 TAM ratio in human cancer tissue and critically evaluates the technicalities and challenges in quantifying this parameter for routine clinical practice. Immunohistochemistry appears to be the preferred methodology for M1/M2 TAM evaluation as it is readily available in clinical laboratories, albeit with certain limitations. Recommendations are made to standardize the quantification of TAMs for better transition into clinical practice and for better comparison among studies in various populations of patients and cancer types. Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in tumor progression unfolds. Better understanding of their polarization into pro-tumoral phenotype to promote tumor growth, tumor angiogenesis, immune evasion, and tumor metastasis has prompted various studies to investigate their clinical significance as a biomarker of predictive and prognostic value across different cancer types. Yet, the methodologies to investigate the polarization phenomena in solid tumor tissue vary. Nonetheless, quantifying the ratio of M1 to M2 TAMs has emerged to be a prevailing parameter to evaluate this polarization phenomena for clinical application. This mini-review focuses on recent studies exploring clinical significance of M1/M2 TAM ratio in human cancer tissue and critically evaluates the technicalities and challenges in quantifying this parameter for routine clinical practice. Immunohistochemistry appears to be the preferred methodology for M1/M2 TAM evaluation as it is readily available in clinical laboratories, albeit with certain limitations. Recommendations are made to standardize the quantification of TAMs for better transition into clinical practice and for better comparison among studies in various populations of patients and cancer types. |
| Author | Citartan, Marimuthu Jayasingam, Sharmilla Devi Thang, Thean Hock Ang, Kai Cheen Ch'ng, Ewe Seng Mat Zin, Anani Aila |
| AuthorAffiliation | 2 Infectious Disease Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia , Kepala Batas , Malaysia 3 Faculty of Applied Sciences, AIMST University , Kedah , Malaysia 4 Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia , Kubang Kerian , Malaysia 1 Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia , Kepala Batas , Malaysia |
| AuthorAffiliation_xml | – name: 4 Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia , Kubang Kerian , Malaysia – name: 3 Faculty of Applied Sciences, AIMST University , Kedah , Malaysia – name: 2 Infectious Disease Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia , Kepala Batas , Malaysia – name: 1 Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia , Kepala Batas , Malaysia |
| Author_xml | – sequence: 1 givenname: Sharmilla Devi surname: Jayasingam fullname: Jayasingam, Sharmilla Devi – sequence: 2 givenname: Marimuthu surname: Citartan fullname: Citartan, Marimuthu – sequence: 3 givenname: Thean Hock surname: Thang fullname: Thang, Thean Hock – sequence: 4 givenname: Anani Aila surname: Mat Zin fullname: Mat Zin, Anani Aila – sequence: 5 givenname: Kai Cheen surname: Ang fullname: Ang, Kai Cheen – sequence: 6 givenname: Ewe Seng surname: Ch'ng fullname: Ch'ng, Ewe Seng |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32039007$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UsFqGzEQXUpKk6Y591Z07MWOVlrtrnooBJM2hoSa4kJvYlY7shVkyZV2A8kX9TMr22lICtVBEjPvvXkw721x5IPHonhf0innrTw3wespo6Wc0lKU7FVxwhivJrLiP4-e_Y-Ls5RuaT61oCXlb4pjziiXlDYnxe_LO3AjDNavyLBGsggOon3IheBJMGQ5bkKcXKQUtIUBe3IDOobtGlaYyNwPgdyUBHyuM7JYow_D_TZ3rCdX4wY8mYHXGMnSpjTiJ7JEvfZWg7ODzbAdcbYG59CvDqzvYcxekMyc3ePIIoIerMZ3xWsDLuHZ43ta_PhyuZxdTa6_fZ3PLq4nuhJymBgBTV3pVvK2awFLwZBVVKCBtq9b01TCVEz2Wusay4a1FTTQacM4k9B1gvLTYn7Q7QPcqm20G4j3KoBV-0KIKwUxG3Ko-qrjkndNJzteGZAgaKupNgZM3ZbYZq3PB63t2G2w1-iHCO6F6MuOt2u1CneqlpLVgmeBj48CMfwaMQ1qY5NG58BjGJNiXHBa5rvO0A_PZz0N-bvqDDg_APL-UoponiAlVbs8qV2e1C5Pap-nzBD_MLQd9snIZq37L-8PkNjTRw |
| CitedBy_id | crossref_primary_10_1186_s12935_023_02980_0 crossref_primary_10_1016_j_humimm_2024_110805 crossref_primary_10_1016_j_immuni_2021_03_022 crossref_primary_10_3389_fonc_2020_615534 crossref_primary_10_3389_fimmu_2020_01731 crossref_primary_10_1186_s12885_024_12948_6 crossref_primary_10_1016_j_archoralbio_2024_106028 crossref_primary_10_3390_biomedicines8110474 crossref_primary_10_3389_fonc_2021_621373 crossref_primary_10_3389_fonc_2021_668349 crossref_primary_10_1002_adma_202300086 crossref_primary_10_3389_fimmu_2022_955841 crossref_primary_10_1016_j_oor_2024_100501 crossref_primary_10_3390_ijms23010430 crossref_primary_10_1158_2159_8290_CD_21_0888 crossref_primary_10_1080_08982104_2024_2315452 crossref_primary_10_3390_molecules26237107 crossref_primary_10_1016_j_phymed_2021_153489 crossref_primary_10_1038_s41388_025_03504_y crossref_primary_10_3390_ijms22052662 crossref_primary_10_1007_s00262_023_03393_8 crossref_primary_10_3389_fimmu_2023_1250258 crossref_primary_10_3390_cancers13030466 crossref_primary_10_3389_fmolb_2024_1340124 crossref_primary_10_3390_ijms22084261 crossref_primary_10_3389_fimmu_2023_1264774 crossref_primary_10_1038_s42003_021_02099_w crossref_primary_10_1016_j_canlet_2022_215979 crossref_primary_10_1016_j_modpat_2023_100128 crossref_primary_10_1038_s41392_025_02124_y crossref_primary_10_3390_vaccines10111963 crossref_primary_10_3390_cells9102334 crossref_primary_10_1016_j_mattod_2023_06_008 crossref_primary_10_1038_s12276_022_00883_0 crossref_primary_10_3389_fonc_2023_1288077 crossref_primary_10_3389_fonc_2020_00621 crossref_primary_10_1007_s00262_025_04030_2 crossref_primary_10_1515_med_2023_0729 crossref_primary_10_1155_2024_8481761 crossref_primary_10_3389_fimmu_2020_01947 crossref_primary_10_3390_v13040654 crossref_primary_10_1002_jso_27487 crossref_primary_10_1016_j_addr_2022_114239 crossref_primary_10_32604_or_2023_030690 crossref_primary_10_3390_cancers13184712 crossref_primary_10_1002_adhm_202100051 crossref_primary_10_1016_j_heliyon_2023_e13211 crossref_primary_10_1016_j_heliyon_2024_e32258 crossref_primary_10_1016_j_cej_2023_148069 crossref_primary_10_1111_febs_16465 crossref_primary_10_3390_biomedicines10061252 crossref_primary_10_1016_j_ijbiomac_2025_144032 crossref_primary_10_1038_s41598_022_24437_6 crossref_primary_10_3390_biomedicines10020301 crossref_primary_10_1038_s41598_021_93467_3 crossref_primary_10_1016_j_jtcvs_2022_07_016 crossref_primary_10_1038_s41698_022_00305_4 crossref_primary_10_1002_mog2_92 crossref_primary_10_1007_s10142_023_01051_x crossref_primary_10_3390_ijms23136994 crossref_primary_10_3389_fimmu_2023_1268939 crossref_primary_10_3389_fonc_2024_1450603 crossref_primary_10_3390_ph18060915 crossref_primary_10_1038_s41388_024_03169_z crossref_primary_10_1186_s13045_021_01087_1 crossref_primary_10_2147_IJN_S279192 crossref_primary_10_3390_cancers12061668 crossref_primary_10_3389_fimmu_2023_1295257 crossref_primary_10_1038_s41523_021_00304_x crossref_primary_10_1038_s41416_025_03137_8 crossref_primary_10_3389_fimmu_2022_837230 crossref_primary_10_1002_advs_202105696 crossref_primary_10_1016_j_jff_2025_106671 crossref_primary_10_1002_advs_202405399 crossref_primary_10_1007_s40618_020_01443_x crossref_primary_10_1007_s13346_025_01970_1 crossref_primary_10_3389_fonc_2023_1270991 crossref_primary_10_3389_fimmu_2022_1071188 crossref_primary_10_1038_s41388_025_03485_y crossref_primary_10_3390_ijms241512400 crossref_primary_10_1016_j_esmogo_2024_100130 crossref_primary_10_3390_cancers13081946 crossref_primary_10_3390_ijms252313167 crossref_primary_10_1111_1759_7714_14937 crossref_primary_10_3390_ijms231810211 crossref_primary_10_1186_s40364_023_00482_9 crossref_primary_10_3389_fimmu_2024_1476565 crossref_primary_10_1038_s41416_021_01652_y crossref_primary_10_1016_j_lfs_2021_119750 crossref_primary_10_3390_cells13231948 crossref_primary_10_3390_ijms24032275 crossref_primary_10_2147_IJN_S337093 crossref_primary_10_3389_pore_2022_1610230 crossref_primary_10_3390_cancers15194770 crossref_primary_10_3389_fmicb_2020_606404 crossref_primary_10_3390_bioengineering10040485 crossref_primary_10_3390_cancers17050723 crossref_primary_10_1186_s12885_022_10431_8 crossref_primary_10_4049_jimmunol_2300029 crossref_primary_10_1111_jcmm_70000 crossref_primary_10_3390_ijms23158603 crossref_primary_10_1038_s41416_023_02238_6 crossref_primary_10_1016_j_humimm_2024_110774 crossref_primary_10_3390_cancers16010196 crossref_primary_10_1097_JS9_0000000000001227 crossref_primary_10_3233_CBM_230170 crossref_primary_10_1038_s41416_022_01933_0 crossref_primary_10_1038_s41598_022_08163_7 crossref_primary_10_1080_2162402X_2024_2364382 crossref_primary_10_3390_gidisord3040020 crossref_primary_10_1210_endocr_bqae059 crossref_primary_10_3389_fphar_2022_875384 crossref_primary_10_3390_cancers14010226 crossref_primary_10_1016_j_expneurol_2021_113895 crossref_primary_10_1093_jrr_rrab037 crossref_primary_10_1002_psp4_70033 crossref_primary_10_1080_1061186X_2024_2410462 crossref_primary_10_1016_j_ijpharm_2022_122547 crossref_primary_10_3389_fimmu_2023_1014778 crossref_primary_10_1111_cup_14155 crossref_primary_10_3389_fphar_2022_875149 crossref_primary_10_1016_j_ejpb_2022_06_014 crossref_primary_10_1186_s13073_024_01401_9 crossref_primary_10_2147_IJGM_S329208 crossref_primary_10_1186_s13045_024_01559_0 crossref_primary_10_1186_s12943_023_01723_z crossref_primary_10_3389_fimmu_2022_874255 crossref_primary_10_3389_fgene_2024_1482929 crossref_primary_10_3390_cancers13092222 crossref_primary_10_1016_j_jconrel_2022_05_004 crossref_primary_10_1186_s12967_021_03012_z crossref_primary_10_3389_fonc_2023_1063051 crossref_primary_10_3390_cancers15143739 crossref_primary_10_4251_wjgo_v14_i9_1637 crossref_primary_10_3389_fphar_2025_1502107 crossref_primary_10_1021_acssynbio_4c00589 crossref_primary_10_3390_ijms21207716 crossref_primary_10_1016_j_bbcan_2025_189434 crossref_primary_10_1002_jex2_70075 crossref_primary_10_1182_bloodadvances_2023009813 crossref_primary_10_1016_j_lfs_2020_118249 crossref_primary_10_1515_hsz_2023_0317 crossref_primary_10_1002_hed_26498 crossref_primary_10_1038_s44276_024_00056_8 crossref_primary_10_1007_s00262_024_03679_5 crossref_primary_10_1245_s10434_023_13384_9 crossref_primary_10_1016_j_jff_2021_104743 crossref_primary_10_1016_j_ijbiomac_2023_124144 crossref_primary_10_1016_j_yexcr_2024_114198 crossref_primary_10_1016_j_jep_2025_119636 crossref_primary_10_1016_j_jss_2025_03_036 crossref_primary_10_1002_cbin_12226 crossref_primary_10_1245_s10434_025_17747_2 crossref_primary_10_1136_jitc_2024_009539 crossref_primary_10_1126_sciadv_adv3316 crossref_primary_10_1016_j_jff_2024_106458 crossref_primary_10_3390_pathogens10080969 crossref_primary_10_1038_s41598_023_28073_6 crossref_primary_10_1002_pros_24432 crossref_primary_10_3390_cancers12071987 crossref_primary_10_1002_cam4_6717 crossref_primary_10_1007_s00018_022_04226_0 crossref_primary_10_3390_ijms241612813 crossref_primary_10_1136_jitc_2024_009765 crossref_primary_10_3892_ijo_2022_5374 crossref_primary_10_1016_j_canlet_2022_216042 crossref_primary_10_1186_s12894_023_01258_x crossref_primary_10_3390_genes13040629 crossref_primary_10_1016_j_semcancer_2021_02_004 crossref_primary_10_3390_dermatopathology9010009 crossref_primary_10_1155_2022_1433323 crossref_primary_10_1016_j_crmeth_2022_100340 crossref_primary_10_1186_s13046_024_02982_4 crossref_primary_10_3390_biomedicines12102243 crossref_primary_10_1016_j_eurpolymj_2024_113333 crossref_primary_10_1007_s12672_023_00697_0 crossref_primary_10_3892_ol_2025_14906 crossref_primary_10_2147_CCID_S358897 crossref_primary_10_3389_fonc_2021_610303 crossref_primary_10_1186_s40364_024_00581_1 crossref_primary_10_1016_j_jtemin_2025_100233 crossref_primary_10_1016_j_wneu_2024_01_063 crossref_primary_10_3390_cells9040919 crossref_primary_10_1007_s12032_023_02066_x crossref_primary_10_1016_j_coph_2023_102404 crossref_primary_10_3390_cancers13010043 crossref_primary_10_1177_03008916231189532 crossref_primary_10_53941_ijddp_2024_100011 crossref_primary_10_3390_ijms25137195 crossref_primary_10_3390_ijms21238984 crossref_primary_10_1136_jitc_2021_004167 crossref_primary_10_1007_s00432_024_05777_4 crossref_primary_10_3390_ma14164660 crossref_primary_10_1080_17435889_2024_2393076 crossref_primary_10_3390_app14041639 crossref_primary_10_1002_lary_29698 crossref_primary_10_1038_s42003_023_05208_z crossref_primary_10_3390_biomedicines12102306 crossref_primary_10_3390_cancers14112749 crossref_primary_10_1038_s41598_025_06799_9 crossref_primary_10_3390_pathogens10111366 crossref_primary_10_1016_j_bcp_2023_115974 crossref_primary_10_1158_1078_0432_CCR_20_1163 crossref_primary_10_19163_2307_9266_2025_13_2_111_127 crossref_primary_10_3389_fphar_2023_1065505 crossref_primary_10_3390_cancers15215175 crossref_primary_10_1186_s12929_022_00855_6 crossref_primary_10_3390_cancers15215294 crossref_primary_10_3390_ijms222112015 crossref_primary_10_1016_j_humimm_2022_02_007 crossref_primary_10_1016_j_freeradbiomed_2021_10_010 crossref_primary_10_15407_biotech15_04_011 crossref_primary_10_1093_jncics_pkae097 crossref_primary_10_1136_jitc_2024_010341 crossref_primary_10_1186_s12951_021_01079_w crossref_primary_10_2147_OTT_S437560 crossref_primary_10_1016_j_ecoenv_2022_113779 crossref_primary_10_1371_journal_pbio_3002188 crossref_primary_10_1007_s12032_021_01602_x crossref_primary_10_3233_TUB_200082 crossref_primary_10_3390_ijms25021180 crossref_primary_10_3390_cancers12113401 crossref_primary_10_1007_s10585_023_10257_z crossref_primary_10_3390_cancers13205072 crossref_primary_10_1002_fsn3_70829 crossref_primary_10_1159_000540473 crossref_primary_10_1155_2022_9009269 crossref_primary_10_1038_s41467_021_24610_x crossref_primary_10_3390_cancers12092652 crossref_primary_10_3389_fimmu_2021_675538 crossref_primary_10_1007_s10549_021_06260_1 crossref_primary_10_1208_s12248_023_00881_8 crossref_primary_10_1002_adbi_202400431 crossref_primary_10_1016_j_ctarc_2020_100274 crossref_primary_10_3389_fsurg_2022_917061 crossref_primary_10_1039_D5BM00342C crossref_primary_10_1016_j_ccell_2021_02_013 crossref_primary_10_3389_fonc_2022_1022716 crossref_primary_10_3892_or_2021_8196 crossref_primary_10_1016_j_bbcan_2023_189005 crossref_primary_10_1038_s41419_025_07610_3 crossref_primary_10_2147_JIR_S384908 crossref_primary_10_1016_j_semcancer_2022_08_004 crossref_primary_10_20538_1682_0363_2024_4_55_63 crossref_primary_10_1016_j_lfs_2025_123601 crossref_primary_10_3389_fcell_2021_687245 crossref_primary_10_1016_j_biopha_2023_114592 crossref_primary_10_3389_fcell_2024_1491282 crossref_primary_10_3390_polym16233390 crossref_primary_10_3389_fimmu_2025_1539780 crossref_primary_10_1016_j_ejmech_2024_116361 crossref_primary_10_1182_bloodadvances_2020003871 crossref_primary_10_1186_s13104_021_05728_z crossref_primary_10_1007_s00281_023_00988_2 crossref_primary_10_15252_emmm_201911131 crossref_primary_10_3390_biomedicines12010121 crossref_primary_10_3390_cancers13040641 crossref_primary_10_3390_cancers12102969 crossref_primary_10_3389_fphar_2022_870347 crossref_primary_10_1111_fcp_70008 crossref_primary_10_3390_cancers15020376 crossref_primary_10_1007_s00262_023_03496_2 crossref_primary_10_1371_journal_pone_0266827 crossref_primary_10_1016_j_isci_2023_106480 crossref_primary_10_1016_j_yexmp_2020_104592 crossref_primary_10_3390_biom10050666 crossref_primary_10_17749_2313_7347_ob_gyn_rep_2025_647 crossref_primary_10_3389_fimmu_2022_830292 crossref_primary_10_1002_pros_24139 crossref_primary_10_1038_s41598_024_65960_y crossref_primary_10_1136_jitc_2022_005968 crossref_primary_10_3390_cimb46090588 crossref_primary_10_3390_biomedicines9111566 crossref_primary_10_3389_fcell_2021_705060 crossref_primary_10_3389_fimmu_2023_1200249 crossref_primary_10_1016_j_bcp_2022_115369 crossref_primary_10_1002_1878_0261_13152 crossref_primary_10_3390_cancers13164004 crossref_primary_10_3390_ijms25052862 crossref_primary_10_1038_s41598_024_54433_x crossref_primary_10_1186_s12935_021_01955_3 crossref_primary_10_1002_advs_202201069 crossref_primary_10_3389_fonc_2021_619517 crossref_primary_10_3390_cancers12102946 crossref_primary_10_3390_cells11233890 crossref_primary_10_3390_jcm11051257 crossref_primary_10_3389_fcell_2022_930933 crossref_primary_10_1007_s00262_024_03646_0 crossref_primary_10_1016_j_biomaterials_2021_121012 crossref_primary_10_1016_j_gene_2024_149000 crossref_primary_10_3390_ijms25063510 crossref_primary_10_1016_j_intimp_2023_110838 crossref_primary_10_1007_s11033_020_06054_6 crossref_primary_10_3390_biology10090854 crossref_primary_10_1038_s42003_024_07276_1 crossref_primary_10_3389_fimmu_2020_621225 crossref_primary_10_1016_j_bcp_2025_117187 crossref_primary_10_3389_fimmu_2021_643771 crossref_primary_10_1007_s00262_022_03316_z crossref_primary_10_3389_fonc_2025_1585935 crossref_primary_10_1155_2021_9927747 crossref_primary_10_1055_s_0044_1787059 crossref_primary_10_3389_fonc_2021_675664 crossref_primary_10_1002_cbf_3981 crossref_primary_10_3389_fonc_2021_736620 crossref_primary_10_1007_s11538_024_01353_6 crossref_primary_10_1016_j_semcancer_2025_05_003 crossref_primary_10_3390_diagnostics10050256 crossref_primary_10_4155_fmc_2021_0332 crossref_primary_10_1016_j_carbpol_2025_123416 crossref_primary_10_1002_wnan_1704 crossref_primary_10_1007_s10439_025_03823_x crossref_primary_10_1186_s13045_021_01198_9 crossref_primary_10_1016_j_intimp_2025_114260 crossref_primary_10_3389_fimmu_2023_1295684 crossref_primary_10_3390_ncrna8010016 crossref_primary_10_1093_neuonc_noac136 crossref_primary_10_1002_kjm2_12651 crossref_primary_10_3390_ijms22147755 crossref_primary_10_3390_molecules29163919 crossref_primary_10_1016_j_intimp_2024_111709 crossref_primary_10_3389_fgene_2022_833013 crossref_primary_10_3389_fonc_2022_632042 crossref_primary_10_1016_j_ecoenv_2023_114600 crossref_primary_10_1158_2326_6066_CIR_23_0999 crossref_primary_10_1111_imm_13529 crossref_primary_10_1007_s00262_021_03062_8 crossref_primary_10_4103_jofs_jofs_29_25 crossref_primary_10_1016_j_prp_2024_155518 crossref_primary_10_17352_2455_8591_000032 crossref_primary_10_3389_fonc_2022_1072739 crossref_primary_10_3389_fonc_2022_963896 crossref_primary_10_1038_s43018_023_00527_w crossref_primary_10_1158_0008_5472_CAN_22_1403 crossref_primary_10_1016_j_intimp_2021_107709 crossref_primary_10_3390_ijms23063214 crossref_primary_10_3389_fonc_2021_654922 crossref_primary_10_3389_fimmu_2021_724429 crossref_primary_10_1038_s41590_022_01267_2 crossref_primary_10_1007_s12272_020_01287_2 crossref_primary_10_1186_s12967_025_06235_6 crossref_primary_10_1186_s12964_024_01701_y crossref_primary_10_1016_j_ctrv_2022_102460 crossref_primary_10_1016_j_apsb_2023_12_004 crossref_primary_10_3390_ijms23126442 crossref_primary_10_1111_febs_70046 crossref_primary_10_1016_j_pdpdt_2023_103792 crossref_primary_10_3390_cells11162578 crossref_primary_10_3390_cancers13205247 crossref_primary_10_1007_s11538_025_01466_6 crossref_primary_10_1016_j_prp_2024_155748 crossref_primary_10_3389_fimmu_2023_1102824 crossref_primary_10_1186_s12885_022_09612_2 crossref_primary_10_3389_fimmu_2021_650427 crossref_primary_10_3390_microorganisms11020288 crossref_primary_10_3389_fimmu_2022_940645 crossref_primary_10_1016_j_bbadis_2023_166695 crossref_primary_10_1080_10717544_2021_1921076 crossref_primary_10_3390_biology10060502 crossref_primary_10_1186_s12951_024_02855_0 crossref_primary_10_1080_08820139_2022_2027439 crossref_primary_10_1016_j_jtbi_2021_110739 crossref_primary_10_7554_eLife_95106_3 crossref_primary_10_1016_j_isci_2025_112752 crossref_primary_10_3390_diseases13070216 crossref_primary_10_1186_s12885_025_14643_6 crossref_primary_10_1016_j_bioadv_2022_213270 crossref_primary_10_1007_s00018_023_04810_y crossref_primary_10_1016_j_bbrc_2024_150950 crossref_primary_10_1007_s13577_022_00792_4 crossref_primary_10_1038_s41368_023_00216_5 crossref_primary_10_3389_fonc_2023_1228426 crossref_primary_10_3390_biomedicines12061317 crossref_primary_10_1038_s41378_022_00370_6 crossref_primary_10_3390_cancers15215116 crossref_primary_10_61958_NMLC1923 crossref_primary_10_1186_s12967_023_04064_z crossref_primary_10_1016_j_prp_2024_155202 crossref_primary_10_3748_wjg_v30_i38_4249 crossref_primary_10_3389_fmed_2022_955599 crossref_primary_10_1016_j_bbadis_2021_166155 crossref_primary_10_1111_iej_14138 crossref_primary_10_1186_s12951_022_01316_w crossref_primary_10_1038_s41467_023_40852_3 crossref_primary_10_3389_fcell_2022_808212 crossref_primary_10_3390_ijms25010663 crossref_primary_10_1007_s10911_020_09456_1 crossref_primary_10_1631_jzus_B2100029 crossref_primary_10_3390_cancers13030423 crossref_primary_10_3390_ijms22042142 crossref_primary_10_1007_s10555_020_09944_0 crossref_primary_10_3390_medsci13030129 crossref_primary_10_1038_s41598_023_36844_4 crossref_primary_10_1186_s40364_023_00537_x crossref_primary_10_3390_ijms22179133 crossref_primary_10_1016_j_pharmr_2025_100074 crossref_primary_10_3389_fimmu_2025_1556209 crossref_primary_10_1016_j_oor_2024_100559 crossref_primary_10_4251_wjgo_v16_i5_1878 crossref_primary_10_1186_s12935_025_03809_8 crossref_primary_10_3390_ijms23126649 crossref_primary_10_3389_fphar_2025_1611234 crossref_primary_10_3389_fimmu_2024_1412076 crossref_primary_10_3389_fimmu_2021_614294 crossref_primary_10_1016_j_jtocrr_2020_100093 crossref_primary_10_1016_j_isci_2023_107952 crossref_primary_10_3389_fcell_2022_830208 crossref_primary_10_3390_biom12010132 crossref_primary_10_3390_cells12010077 crossref_primary_10_3390_diagnostics11040628 crossref_primary_10_1002_advs_202205803 crossref_primary_10_37349_ei_2025_1003205 crossref_primary_10_7554_eLife_95106 crossref_primary_10_1007_s12272_023_01454_1 crossref_primary_10_3390_cells10040960 crossref_primary_10_4103_jcrt_jcrt_2670_22 crossref_primary_10_3892_etm_2022_11577 |
| Cites_doi | 10.1158/0008-5472.CAN-14-3587 10.7150/jca.25155 10.1038/s41598-019-47375-2 10.1371/journal.pone.0170042 10.18632/oncotarget.17061 10.3389/fonc.2019.00656 10.1371/journal.pone.0050946 10.2217/fon-2018-0669 10.5582/bst.2019.01003 10.4238/gmr15049040 10.7314/APJCP.2013.14.2.1003 10.1186/bcr2615 10.18632/oncotarget.9625 10.1002/JLB.3RU1018-378RR 10.1016/j.ymeth.2014.08.016 10.1371/journal.pone.0134122 10.1007/s12307-015-0174-x 10.1055/s-0030-1255354 10.1038/ni.1937 10.1016/j.ctrv.2018.08.010 10.4161/21624011.2014.946818 10.4049/jimmunol.172.5.2731 10.1186/s13058-015-0621-0 10.1097/PAP.0b013e3181f8957c 10.1245/s10434-014-3601-1 10.1371/journal.pone.0124531 10.1615/CritRevImmunol.v32.i6.10 10.4048/jbc.2019.22.e5 10.1007/s12094-011-0630-0 10.1126/science.312.5782.1874b 10.1371/journal.pone.0208602 10.3389/fimmu.2019.01462 10.3390/molecules24010009 10.1245/s10434-016-5244-x 10.1590/1807-3107BOR-2016.vol30.0095 10.1186/s13045-019-0760-3 10.18632/oncotarget.15736 10.1101/665307 10.1369/jhc.6P7080.2006 10.18632/oncotarget.26775 10.1038/s41598-017-08121-8 10.1038/nature12034 10.18632/oncotarget.22340 10.1016/j.ygyno.2017.07.007 10.1186/s12885-018-4457-8 10.1172/JCI59643 10.1016/j.neo.2019.01.005 10.1111/jcmm.12787 10.1371/journal.pone.0136654 10.1371/journal.pone.0080908 10.1159/000486816 10.1245/s10434-011-1609-3 10.1177/1933719115570912 10.1002/hon.2142 10.1097/MD.0000000000002636 10.3390/ijms17030320 10.1016/j.humpath.2017.09.001 10.1084/jem.20150295 10.1155/2015/816460 10.1038/bjc.2017.356 10.1177/0192623311419163 10.4161/jkst.23820 10.1186/s12885-015-1587-0 10.1158/1078-0432.CCR-09-2904 10.1007/978-3-319-26666-4_12 10.18632/oncotarget.15630 10.1016/B978-0-12-801919-1.00010-5 10.1182/blood.V118.21.1657.1657 10.2147/CMAR.S196951 10.1189/jlb.1106702 10.1371/journal.pone.0121521 10.4132/jptm.2016.08.08 10.1002/path.2527 10.7150/jca.30102 10.3389/fimmu.2019.01875 10.18632/oncotarget.13055 10.1186/s12885-015-1114-3 10.1309/QHD6YFN81KQXUUH6 10.4049/jimmunol.1402603 10.1007/s11926-015-0554-8 10.1007/s12032-014-0352-6 10.1136/gutjnl-2015-309193 10.1186/1757-2215-7-19 10.4049/jimmunol.1701135 10.1111/jcmm.12109 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng. Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng. 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng |
| Copyright_xml | – notice: Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng. – notice: Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng. 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fonc.2019.01512 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_d4b393b7b9b34fa9a508c0cffaf681e8 PMC6992653 32039007 10_3389_fonc_2019_01512 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM ACXDI IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c459t-f5a764c8938b8ae152e2405efa8d68f745f429dccc6e17284a7abcf2329abb503 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 482 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000512187400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2234-943X |
| IngestDate | Fri Oct 03 12:52:07 EDT 2025 Thu Aug 21 13:20:59 EDT 2025 Fri Sep 05 11:51:47 EDT 2025 Thu Apr 03 07:02:18 EDT 2025 Sat Nov 29 01:49:15 EST 2025 Tue Nov 18 22:02:42 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | CD163 M1 M2 cancer immunohistochemistry CD68 tumor-associated macrophages |
| Language | English |
| License | Copyright © 2020 Jayasingam, Citartan, Thang, Mat Zin, Ang and Ch'ng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-f5a764c8938b8ae152e2405efa8d68f745f429dccc6e17284a7abcf2329abb503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Mei Lan Tan, University of Science, Malaysia Reviewed by: Till Adhikary, University of Marburg, Germany; Guoguang Zheng, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Rathindranath Baral, Chittaranjan National Cancer Institute, India This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology |
| OpenAccessLink | https://doaj.org/article/d4b393b7b9b34fa9a508c0cffaf681e8 |
| PMID | 32039007 |
| PQID | 2353012356 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d4b393b7b9b34fa9a508c0cffaf681e8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6992653 proquest_miscellaneous_2353012356 pubmed_primary_32039007 crossref_primary_10_3389_fonc_2019_01512 crossref_citationtrail_10_3389_fonc_2019_01512 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-24 |
| PublicationDateYYYYMMDD | 2020-01-24 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in oncology |
| PublicationTitleAlternate | Front Oncol |
| PublicationYear | 2020 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Yuan (B14) 2017; 147 Mantovani (B24) 2015; 212 Leong (B81) 2010; 17 Zhang (B38) 2012; 7 Wang (B34) 2011; 18 Zhang (B40) 2014; 7 Zhang (B32) 2016; 95 Stack (B48) 2014; 70 Mestas (B83) 2004; 172 Wynn (B62) 2010; 30 Specht (B46) 2019; 665307 Gerrick (B85) 2018; 13 Rakaee (B66) 2019; 21 Lin (B9) 2019; 12 Dong (B21) 2016; 17 Zheng (B6) 2017; 8 Pantano (B37) 2013; 17 Di Caro (B15) 2016; 65 Drew (B67) 2015 Xu (B72) 2014; 21 Buitrago (B77) 2015; 10 Wang (B61) 2019; 10 Lúcio (B70) 2016; 30 Shi (B80) 2007; 55 Yu (B16) 2019; 11 B78 Mills (B7) 2012; 32 Cui (B36) 2013; 14 Petrillo (B39) 2015; 10 Yin (B29) 2017; 12 Hu (B60) 2017; 8 Barros (B41) 2015; 10 Yagnik (B20) 2019; 10 Dumars (B64) 2016; 7 Pinto (B50) 2019; 10 Viola (B52) 2019; 10 Sousa (B68) 2015; 17 Tuominen (B87) 2010; 12 Wang (B4) 2018; 106 Shu (B69) 2016; 20 Yu (B74) 2019; 13 Stifano (B58) 2016; 18 Mori (B76) 2015; 15 Roszer (B57) 2015; 2015 van Dalen (B3) 2018; 24 Zhang (B25) 2010; 16 Rauch (B56) 2013; 2 Aras (B1) 2017; 117 Li (B13) 2019; 15 Honkanen (B8) 2019; 9 Xu (B28) 2015; 194 Bertani (B45) 2017; 7 Kim (B47) 2016; 50 Biswas (B5) 2010; 11 Zhong (B30) 2018; 45 Wang (B19) 2016; 15 Kelly (B73) 2015; 22 Jeong (B23) 2019; 22 Yang (B79) 2018; 9 Ley (B55) 2017; 199 Lee (B75) 2018; 18 Qiu (B12) 2018; 70 Kumar (B49) 2019; 9 Sica (B51) 2012; 122 Schneemann (B84) 2007; 81 Zhao (B17) 2017; 8 Lin (B71) 2016; 23 Helm (B53) 2014; 3 Nathan (B54) 2006; 312 Yang (B27) 2015; 32 Osinsky (B33) 2011; 13 Dunstan (B44) 2011; 39 Hallam (B10) 2011; 118 Hughes (B26) 2015; 75 Wu (B18) 2016; 7 Hamilton (B86) 2009; 218 Marchesi (B65) 2015; 33 Barros (B43) 2013; 8 Cassetta (B11) 2016; 899 Lin (B35) 2015; 15 Wu (B31) 2015; 10 Klingen (B22) 2017; 69 Jiang (B59) 2016; 9 Almatroodi (B63) 2016; 9 Chen (B42) 2017; 8 Lau (B82) 2004; 122 Wynn (B2) 2013; 496 |
| References_xml | – volume: 75 start-page: 3479 year: 2015 ident: B26 article-title: Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3587 – volume: 9 start-page: 2308 year: 2018 ident: B79 article-title: Stromal infiltration of tumor-associated macrophages conferring poor prognosis of patients with basal-like breast carcinoma publication-title: J Cancer. doi: 10.7150/jca.25155 – volume: 9 start-page: 1 year: 2019 ident: B8 article-title: Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer publication-title: Sci Rep. doi: 10.1038/s41598-019-47375-2 – volume: 12 start-page: e0170042 year: 2017 ident: B29 article-title: The prognostic and clinicopathological significance of tumor-associated macrophages in patients with gastric cancer: a meta-analysis publication-title: PLoS ONE. doi: 10.1371/journal.pone.0170042 – volume: 8 start-page: 48436 year: 2017 ident: B6 article-title: Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy publication-title: Oncotarget. doi: 10.18632/oncotarget.17061 – volume: 9 start-page: 656 year: 2019 ident: B49 article-title: Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis publication-title: Front Oncol. doi: 10.3389/fonc.2019.00656 – volume: 7 start-page: e50946 year: 2012 ident: B38 article-title: Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature publication-title: PLoS ONE. doi: 10.1371/journal.pone.0050946 – volume: 15 start-page: 2303 year: 2019 ident: B13 article-title: Prognostic impact of tumor-associated macrophage infiltration in esophageal cancer: a meta-analysis publication-title: Future Oncol. doi: 10.2217/fon-2018-0669 – volume: 13 start-page: 58 year: 2019 ident: B74 article-title: Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: possible immunotherapy implications publication-title: Biosci Trends. doi: 10.5582/bst.2019.01003 – volume: 15 start-page: gmr15049040 year: 2016 ident: B19 article-title: Prognostic significance of tumor-associated macrophage infiltration in gastric cancer: a meta-analysis publication-title: Genet Mol Res. doi: 10.4238/gmr15049040 – volume: 14 start-page: 1003 year: 2013 ident: B36 article-title: Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer publication-title: Asian Pac J Cancer Prev. doi: 10.7314/APJCP.2013.14.2.1003 – volume: 12 start-page: R56 year: 2010 ident: B87 article-title: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 publication-title: Breast Cancer Res. doi: 10.1186/bcr2615 – volume: 7 start-page: 40451 year: 2016 ident: B18 article-title: Inverse role of distinct subsets and distribution of macrophage in lung cancer prognosis: a meta-analysis publication-title: Oncotarget. doi: 10.18632/oncotarget.9625 – volume: 106 start-page: 345 year: 2018 ident: B4 article-title: M2b macrophage polarization and its roles in diseases publication-title: J Leukoc Biol doi: 10.1002/JLB.3RU1018-378RR – volume: 70 start-page: 46 year: 2014 ident: B48 article-title: Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis publication-title: Methods. doi: 10.1016/j.ymeth.2014.08.016 – volume: 10 start-page: e0134122 year: 2015 ident: B31 article-title: Macrophage infiltration induces gastric cancer invasiveness by activating the β-catenin pathway publication-title: PLoS ONE. doi: 10.1371/journal.pone.0134122 – volume: 9 start-page: 10784 year: 2016 ident: B59 article-title: Prognostic value of tumor-associated macrophages in classic Hodgkin's lymphoma: systematic review and meta-analysis publication-title: Int J Clin Exp Med. – volume: 9 start-page: 1 year: 2016 ident: B63 article-title: Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC publication-title: Cancer Microenviron. doi: 10.1007/s12307-015-0174-x – volume: 30 start-page: 245 year: 2010 ident: B62 article-title: Macrophages: master regulators of inflammation and fibrosis publication-title: Semin Liver Dis. doi: 10.1055/s-0030-1255354 – volume: 11 start-page: 889 year: 2010 ident: B5 article-title: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm publication-title: Nat Immunol. doi: 10.1038/ni.1937 – volume: 70 start-page: 178 year: 2018 ident: B12 article-title: Tumor-associated macrophages in breast cancer: innocent bystander or important player? publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2018.08.010 – volume: 3 start-page: e946818 year: 2014 ident: B53 article-title: M1 and M2: there is no good and bad—How macrophages promote malignancy-associated features in tumorigenesis publication-title: Oncoimmunology. doi: 10.4161/21624011.2014.946818 – volume: 172 start-page: 2731 year: 2004 ident: B83 article-title: Of mice and not men: differences between mouse and human immunology publication-title: J Immunol. doi: 10.4049/jimmunol.172.5.2731 – volume: 17 start-page: 101 year: 2015 ident: B68 article-title: Human breast cancer cells educate macrophages toward the M2 activation status publication-title: Breast Cancer Res. doi: 10.1186/s13058-015-0621-0 – volume: 17 start-page: 404 year: 2010 ident: B81 article-title: Immunohistology—past, present, and future publication-title: Adv Anat Pathol. doi: 10.1097/PAP.0b013e3181f8957c – volume: 21 start-page: 3142 year: 2014 ident: B72 article-title: Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma publication-title: Ann Surg Oncol. doi: 10.1245/s10434-014-3601-1 – volume: 10 start-page: e0124531 year: 2015 ident: B41 article-title: Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival publication-title: PLoS ONE. doi: 10.1371/journal.pone.0124531 – volume: 32 start-page: 463 year: 2012 ident: B7 article-title: M1 and M2 macrophages: oracles of health and disease publication-title: Crit Rev Immunol. doi: 10.1615/CritRevImmunol.v32.i6.10 – volume: 22 start-page: 38 year: 2019 ident: B23 article-title: Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer publication-title: J Breast Cancer. doi: 10.4048/jbc.2019.22.e5 – volume: 13 start-page: 133 year: 2011 ident: B33 article-title: Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival publication-title: Clin Transl Oncol. doi: 10.1007/s12094-011-0630-0 – volume: 312 start-page: 1874 year: 2006 ident: B54 article-title: Role of iNOS in human host defense publication-title: Science. doi: 10.1126/science.312.5782.1874b – volume: 13 start-page: e0208602 year: 2018 ident: B85 article-title: Transcriptional profiling identifies novel regulators of macrophage polarization publication-title: PLoS ONE. doi: 10.1371/journal.pone.0208602 – volume: 10 start-page: 1462 year: 2019 ident: B52 article-title: The metabolic signature of macrophage responses publication-title: Front Immunol. doi: 10.3389/fimmu.2019.01462 – volume: 24 start-page: E9 year: 2018 ident: B3 article-title: Molecular repolarisation of tumour-associated macrophages publication-title: Molecules. doi: 10.3390/molecules24010009 – volume: 23 start-page: 3071 year: 2016 ident: B71 article-title: The prognostic significance of pSTAT1 and CD163 expressions in surgically resected stage 1 pulmonary squamous cell carcinomas publication-title: Ann Surg Oncol. doi: 10.1245/s10434-016-5244-x – volume: 30 start-page: e95 year: 2016 ident: B70 article-title: Tumor-associated macrophages (TAMs): clinical-pathological parameters in squamous cell carcinomas of the lower lip publication-title: Braz. Oral Res. doi: 10.1590/1807-3107BOR-2016.vol30.0095 – volume: 12 start-page: 76 year: 2019 ident: B9 article-title: Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications publication-title: J Hematol Oncol. doi: 10.1186/s13045-019-0760-3 – volume: 8 start-page: 30576 year: 2017 ident: B17 article-title: Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature publication-title: Oncotarget. doi: 10.18632/oncotarget.15736 – volume: 665307 year: 2019 ident: B46 article-title: High-throughput single-cell proteomics quantifies the emergence of macrophage heterogeneity publication-title: bioRxiv. doi: 10.1101/665307 – volume: 55 start-page: 105 year: 2007 ident: B80 article-title: Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis publication-title: J Histochem Cytochem. doi: 10.1369/jhc.6P7080.2006 – volume: 10 start-page: 2212 year: 2019 ident: B20 article-title: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes publication-title: Oncotarget. doi: 10.18632/oncotarget.26775 – volume: 7 start-page: 8965 year: 2017 ident: B45 article-title: Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis publication-title: Sci Rep. doi: 10.1038/s41598-017-08121-8 – volume: 496 start-page: 445 year: 2013 ident: B2 article-title: Macrophage biology in development, homeostasis and disease publication-title: Nature. doi: 10.1038/nature12034 – volume: 8 start-page: 112685 year: 2017 ident: B42 article-title: Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma publication-title: Oncotarget. doi: 10.18632/oncotarget.22340 – volume: 147 start-page: 181 year: 2017 ident: B14 article-title: Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2017.07.007 – volume: 18 start-page: 535 year: 2018 ident: B75 article-title: M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas publication-title: BMC Cancer. doi: 10.1186/s12885-018-4457-8 – volume: 122 start-page: 787 year: 2012 ident: B51 article-title: Macrophage plasticity and polarization: in vivo veritas publication-title: J Clin Invest. doi: 10.1172/JCI59643 – volume: 21 start-page: 282 year: 2019 ident: B66 article-title: Prognostic value of macrophage phenotypes in resectable non–small cell lung cancer assessed by multiplex immunohistochemistry publication-title: Neoplasia. doi: 10.1016/j.neo.2019.01.005 – volume: 20 start-page: 1024 year: 2016 ident: B69 article-title: Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection publication-title: J Cell Mol Med. doi: 10.1111/jcmm.12787 – volume: 10 start-page: e0136654 year: 2015 ident: B39 article-title: Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer publication-title: PLoS ONE. doi: 10.1371/journal.pone.0136654 – volume: 8 start-page: e80908 year: 2013 ident: B43 article-title: Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages publication-title: PLoS ONE. doi: 10.1371/journal.pone.0080908 – volume: 45 start-page: 356 year: 2018 ident: B30 article-title: The role of tumor-associated macrophages in colorectal carcinoma progression publication-title: Cell Physiol Biochem. doi: 10.1159/000486816 – volume: 18 start-page: 2585 year: 2011 ident: B34 article-title: Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection publication-title: Ann Surg Oncol. doi: 10.1245/s10434-011-1609-3 – volume: 22 start-page: 948 year: 2015 ident: B73 article-title: Type 2 endometrial cancer is associated with a high density of tumor-associated macrophages in the stromal compartment publication-title: Reprod Sci. doi: 10.1177/1933719115570912 – volume: 33 start-page: 110 year: 2015 ident: B65 article-title: High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma publication-title: Hematol Oncol. doi: 10.1002/hon.2142 – volume: 95 start-page: e2636 year: 2016 ident: B32 article-title: High infiltration of tumor-associated macrophages influences poor prognosis in human gastric cancer patients, associates with the phenomenon of EMT publication-title: Medicine. doi: 10.1097/MD.0000000000002636 – volume: 17 start-page: 320 year: 2016 ident: B21 article-title: CD86+/CD206+, diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis publication-title: Int J Mol Sci. doi: 10.3390/ijms17030320 – volume: 69 start-page: 72 year: 2017 ident: B22 article-title: Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer publication-title: Hum Pathol. doi: 10.1016/j.humpath.2017.09.001 – volume: 212 start-page: 435 year: 2015 ident: B24 article-title: The interaction of anticancer therapies with tumor-associated macrophages publication-title: J Exp Med. doi: 10.1084/jem.20150295 – volume: 2015 start-page: 816460 year: 2015 ident: B57 article-title: Understanding the mysterious M2 macrophage through activation markers and effector mechanisms publication-title: Mediators Inflamm. doi: 10.1155/2015/816460 – volume: 117 start-page: 1583 year: 2017 ident: B1 article-title: TAMeless traitors: macrophages in cancer progression and metastasis publication-title: Br J Cancer. doi: 10.1038/bjc.2017.356 – volume: 39 start-page: 988 year: 2011 ident: B44 article-title: The use of immunohistochemistry for biomarker assessment—can it compete with other technologies? publication-title: Toxicol Pathol. doi: 10.1177/0192623311419163 – volume: 2 start-page: e23820 year: 2013 ident: B56 article-title: The regulation of inflammation by interferons and their STATs publication-title: JAKSTAT. doi: 10.4161/jkst.23820 – volume: 15 start-page: 573 year: 2015 ident: B76 article-title: Tumor-associated macrophages in oral premalignant lesions coexpress CD163 and STAT1 in a Th1-dominated microenvironment publication-title: BMC Cancer. doi: 10.1186/s12885-015-1587-0 – volume: 16 start-page: 3420 year: 2010 ident: B25 article-title: Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-09-2904 – volume: 899 start-page: 211 year: 2016 ident: B11 article-title: Isolation of mouse and human tumor-associated macrophages publication-title: Adv Exp Med Biol. doi: 10.1007/978-3-319-26666-4_12 – volume: 8 start-page: 21526 year: 2017 ident: B60 article-title: CD163 as a marker of M2 macrophage, contribute to predict aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma publication-title: Oncotarget. doi: 10.18632/oncotarget.15630 – volume-title: Current Laboratory Techniques in Rabies Diagnosis, Research and Prevention. year: 2015 ident: B67 article-title: Immunohistochemistry doi: 10.1016/B978-0-12-801919-1.00010-5 – volume: 118 start-page: 1657 year: 2011 ident: B10 article-title: Manipulating tumor associated macrophages (TAM) in a mouse model of B-cell non-hodgkin lymphoma (NHL) publication-title: Blood doi: 10.1182/blood.V118.21.1657.1657 – volume: 11 start-page: 4041 year: 2019 ident: B16 article-title: Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis publication-title: Cancer Manag Res. doi: 10.2147/CMAR.S196951 – volume: 81 start-page: 579 year: 2007 ident: B84 article-title: Macrophage biology and immunology: man is not a mouse publication-title: J Leukoc Biol. doi: 10.1189/jlb.1106702 – volume: 10 start-page: e0121521 year: 2015 ident: B77 article-title: Small RNA sequencing for profiling microRNAs in long-term preserved formalin-fixed and paraffin-embedded non-small cell lung cancer tumor specimens publication-title: PLoS ONE. doi: 10.1371/journal.pone.0121521 – volume: 50 start-page: 411 year: 2016 ident: B47 article-title: Immunohistochemistry for pathologists: protocols, pitfalls, and tips publication-title: J Pathol Transl Med. doi: 10.4132/jptm.2016.08.08 – volume: 218 start-page: 285 year: 2009 ident: B86 article-title: Do we see what we think we see? The complexities of morphological assessment publication-title: J Pathol. doi: 10.1002/path.2527 – volume: 10 start-page: 3239 year: 2019 ident: B61 article-title: High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens publication-title: J Cancer. doi: 10.7150/jca.30102 – volume: 10 start-page: 1875 year: 2019 ident: B50 article-title: The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer publication-title: Front Immunol. doi: 10.3389/fimmu.2019.01875 – volume: 7 start-page: 78343 year: 2016 ident: B64 article-title: Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma publication-title: Oncotarget. doi: 10.18632/oncotarget.13055 – volume: 15 start-page: 128 year: 2015 ident: B35 article-title: The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression publication-title: BMC Cancer. doi: 10.1186/s12885-015-1114-3 – volume: 122 start-page: 794 year: 2004 ident: B82 article-title: CD163A specific marker of macrophages in paraffin-embedded tissue samples publication-title: Am J Clin Pathol. doi: 10.1309/QHD6YFN81KQXUUH6 – volume: 194 start-page: 4997 year: 2015 ident: B28 article-title: Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype publication-title: J Immunol. doi: 10.4049/jimmunol.1402603 – volume: 18 start-page: 2 year: 2016 ident: B58 article-title: Macrophage involvement in systemic sclerosis: do we need more evidence? publication-title: Curr Rheumatol Rep. doi: 10.1007/s11926-015-0554-8 – volume: 32 start-page: 352 year: 2015 ident: B27 article-title: Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway publication-title: Med Oncol. doi: 10.1007/s12032-014-0352-6 – volume: 65 start-page: 1710 year: 2016 ident: B15 article-title: Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy publication-title: Gut. doi: 10.1136/gutjnl-2015-309193 – volume: 7 start-page: 19 year: 2014 ident: B40 article-title: A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients publication-title: J Ovarian Res. doi: 10.1186/1757-2215-7-19 – volume: 199 start-page: 2191 year: 2017 ident: B55 article-title: M1 means kill; M2 means heal publication-title: J Immunol. doi: 10.4049/jimmunol.1701135 – ident: B78 – volume: 17 start-page: 1415 year: 2013 ident: B37 article-title: The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients publication-title: J Cell Mol Med. doi: 10.1111/jcmm.12109 |
| SSID | ssj0000650103 |
| Score | 2.6580732 |
| SecondaryResourceType | review_article |
| Snippet | Tumor-associated macrophages (TAMs) as immune cells within the tumor microenvironment have gained much interests as basic science regarding their roles in... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1512 |
| SubjectTerms | CD163 CD68 immunohistochemistry Oncology tumor-associated macrophages |
| Title | Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32039007 https://www.proquest.com/docview/2353012356 https://pubmed.ncbi.nlm.nih.gov/PMC6992653 https://doaj.org/article/d4b393b7b9b34fa9a508c0cffaf681e8 |
| Volume | 9 |
| WOSCitedRecordID | wos000512187400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2234-943X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000650103 issn: 2234-943X databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2234-943X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000650103 issn: 2234-943X databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwELVghRAXxDdhl5WROHDJbhrbsc1tqboCia56KFJvke3YtNLioH7scX8PP3NnnLRqEYgLl0hJbMXKm2TejO03hLxXTVn5IKo8MKsxdSNzayTLS2DjtjBeGZsk87_Kqys1m-nJXqkvXBPWyQN3L-684ZZpZqXVlvFgtAFG4QoXggmVGvi0zRdYz14w1f2DBRYw6LR8IArT56GNqFg40GcFOrkDN5TU-v9EMX9fKbnnei6fkMc9Z6QX3Vifkns-PiMPx_2s-HPya9RLdsfvFPgcnWC42u-vpG2g082PdplvgfANHRss3DWHX8mKfonrlo4H1ES4XtLJ3McW87Iruog0pfjpEC1jSacJo480ZeMR2yTGmjoOtyVZUi9cZQQDo73m6DWd9FuxXpBvl6Pp8HPeV2DIHRd6nQdhZMUdcBpllfHg6z0wAOGDUU2lguQigD9rnHOVx0JX3EhjXQCWpo21omAvyVFso39NaAOtFPBD30jOmZe2kR5CJ82YLeHEZ-RsC0jtenlyrJJxXUOYggjWiGCNCNYJwYx82HX42Slz_L3pJ0R41wwltdMFMLS6N7T6X4aWkXdb-6jhE8R5FRN9u1nVJRMs7TmuMvKqs5fdo1hZMA08LCPywJIOxnJ4Jy7mSea70rqsBHvzPwZ_TB6VmCgoBnnJT8jRernxb8kDd7NerJan5L6cqdP0BcFxfDu6A3eIJlQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+the+Polarization+of+Tumor-Associated+Macrophages+Into+M1+and+M2+Phenotypes+in+Human+Cancer+Tissue%3A+Technicalities+and+Challenges+in+Routine+Clinical+Practice&rft.jtitle=Frontiers+in+oncology&rft.au=Jayasingam%2C+Sharmilla+Devi&rft.au=Citartan%2C+Marimuthu&rft.au=Thang%2C+Thean+Hock&rft.au=Mat+Zin%2C+Anani+Aila&rft.date=2020-01-24&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=9&rft_id=info:doi/10.3389%2Ffonc.2019.01512&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2019_01512 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |